http://www.cureparkinsons.org.ukLatest content from parkinsons.en-gbhttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38044&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38044&tid=rssTue, 10 Feb 2009 09:33:50 GMT   Dr Roger Barker - Heterogeneity It is now commonly held that there could be any number of causes of Parkinson’s Disease. Dr Roger Barker is an exciting new talent in the world of neurology who hopes to increase recognition of the full range and variety of symptoms which can be segregated into distinct sub types so that the disease can be treated in a more individual and targeted manner.  No two patients with Parkinson’s have the same symptoms and this programme of research will address this issue ensuring that patients are both treated according to the nature of their disease and will only enter clinical trials appropriate to them.   Dr Jon Brotchie – Novel therapies for Parkinson’s A five year programme of dynamic research being undertaken by one of the most charismatic and brilliant Parkinson’s scientists:  Dr Jonathon Brotchie is confident of identifying several novel therapies for Parkinson’s from his superb...http://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42270&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42270&tid=rssTue, 04 Aug 2009 13:45:42 GMT The Cure Parkinson's Trust is determined to facilitate research from concept to treatment and accelerating the regulatory process forms a part of this. This complex topic was discussed at our Medicine and Me patient conference in October 2008. Professor Alastair Breckbridge, Chairman of the MHRA ( Medicines and Healthcare products Regulatory Agency) was in attendance to answer  questions from people with parkinson's on the MHRA process. Following a lively discussion at the meeting, this continues to be an area of interest and involvement for us. Bringing new therapies to market is a complex process, the MHRA's brochure explains in more detail - Click here for the brochure. You may also be interested to see the NICE ( National Institute for Health & Clinical Excellence) guidelines as these too have a major impact on what drugs are available to people with parkinson's. Click here for further details. http://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38518&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38518&tid=rssTue, 04 Aug 2009 13:45:24 GMT The Cure Parkinson’s Trust’s Head of Research, Dr Richard Wyse, who is also head of the genetics section of the Royal Society of Medicine, is enthusiastic about a new Genetics study into Parkinson’s disease that has been funded by The Wellcome Foundation and is being carried out in the UK and USA simultaneously. Our understanding of many diseases has been greatly enhanced by genetic discoveries since the human genome was mapped in 1994.  Scientists discovered that the particular function of each type of specialised cell was defined by its genes, but modified by another molecule called RNA which produces proteins in the cell.  This acts as the control system within the cells. Through studying our genes and RNA we have the opportunity to analyse the massive, but tiny cellular control system, and particularly how it is affected when diseased.   The Wellcome Foundation study into Parkinson’s is timely.  Parkinson’s research is...http://www.cureparkinsons.org.uk/redirect.aspx?module=0&id=0:37633&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=0&id=0:37633&tid=rssTue, 04 Aug 2009 13:57:40 GMThttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42236&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42236&tid=rssTue, 28 Jul 2009 16:52:23 GMT Over the past few months aspects surrounding the supplementary oral administration of Vitamin D for PD has generated interest within the PD community. The core rationale for this is summarised by Marion Evatt's 2008 report in Archives of Neurology which demonstrated that a significant proportion of PD patients had deficient plasma levels of Vitamin D. The sometimes-linked notion in the posts was that Vitamin D may possess a direct protective action on neurones.    The Cure Parkinsons Trust is also very interested, and active, in Vitamin D research. The fact that several diverse reports (Surmeier, Ritz, Rodnitzky and others) have shown calcium channel blockers offer very substantial protection against PD, and also that they provide phenomenal protection and reversal of symptoms in experimental models of PD (Surmeier), has led to the recent commencement of a major clinical trial in PD patients on the anti-hypertension therapy, Isradipine. This trial is scheduled to...http://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42157&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:42157&tid=rssThu, 16 Jul 2009 17:54:52 GMT For those people with Parkinson’s, the word ‘cure’ is an emotive one and is interpreted in many ways. Ultimately a cure or cures will be realised by reversing the progressive nature of the condition.  The primary goal is to make a positive impact on those living with Parkinson’s so that a person’s expectations for the recovery of their own quality of life is realised. Cure or cures can involve any or all of the following key milestones: Slowing symptom degeneration Alleviation of symptoms and side effects Stopping the disease process Regeneration, repair, regression of the disease Isolation and treatment of causes including genetic prediction Prevention Total eradication of Parkinson’s disease and Parkinsonism The key to achieving any of the above is through innovation and through responding to the real-life needs of people with Parkinson’s.  Once novel treatments have been identified, it is critical that they are nurtured through the development process and delivered quickly but safely...http://www.cureparkinsons.org.uk/redirect.aspx?module=0&id=0:53942&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=0&id=0:53942&tid=rssThu, 16 Jul 2009 17:52:26 GMThttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:39842&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:39842&tid=rssWed, 29 Oct 2008 11:01:59 GMT This November, The Cure Parkinsons Trust will be hosting a two day conference at the Royal Society of Medicine in London where leading scientists and clinicians from around the world will discuss the potential of using anti-inflammatory and anti-oxidative therapies to treat Parkinson’s Disease, and most especially, to slow its progression. The past 2-3 years have seen enormous interest in this promising field of research, and several different drug and lifestyle nutritional approaches have emerged from it which offer both theoretical and tangible, now proven, benefits.   There is ample evidence that an inflammatory response occurs in brain cells in Parkinson’s Disease. Some scientists say it is a fundamental part of the disease process, others feel it is just a response to it. Whatever the truth, many agree that this inflammation increases local damage to brain cells, and therefore accelerates disease progression.  Accordingly, many are interested in using some of...http://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38516&tid=rsshttp://www.cureparkinsons.org.uk/redirect.aspx?module=3&doc=0:38516&tid=rssMon, 01 Jan 0001 00:00:00 GMT Medical advances are inspiring us all to hope for so much from the new generation of medicine. The sudden burst of progress driven by major research programmes such as the Human Genome Project, and its successors, provide fresh understanding of the causes of disease and clues for cures. New treatments like gene therapy are providing clinicians with promising new options. And minor breakthroughs provide new hope in specific areas: new mechanisms of getting drugs past the brain’s delicate defences are critical for Parkinson’s Disease. It seems that, finally, a cure for Parkinson’s is within sight. But the reality is somewhat different. The mechanisms for developing new drugs simply are not keeping pace with advances in medicine. The grant-making processes remain slow-moving and conservative, with an in-built bias for clusters of well-documented drugs which means studying the same 40-year old ameliorative remedies over and over again. Patient’s need to be involved...